대한신장학회

Skip Navigation: Skip to contents

KOR
ENG
전체메뉴보기

간행물 검색

현재 페이지 경로

HOME
간행물
간행물 검색

논문분류	춘계학술대회 초록집
제목	Differential Effects of SGLT2 Inhibitors on Contrast-Associated Acute Kidney Injury According to Hemoglobin and Age: A Propensity-Score Matched Analysis
저자	Byungkwan Jung
출판정보	2026; 2026(1):
키워드	SGLT2 inhibitor, contrast-associated acute kidney injury, effect modification, hemoglobin, age
초록	Objectives: Sodium-glucose cotransporter-2 inhibitors (SGLT2i) are widely used in type 2 diabetes, heart failure, and chronic kidney disease. Given their expanding indications, SGLT2i are increasingly prescribed to patients undergoing contrast-enhanced procedures. However, their impact on contrast-associated acute kidney injury (CA-AKI) remains uncertain. We evaluated the overall risk of CA-AKI in SGLT2i users and identified clinical effect modifiers. Methods: In this single-center propensity-score matched study (2007–2025), 346 SGLT2i users and 1,979 matched non-users were selected from 7,853 angiography patients using variable-ratio matching (caliper 0.2). Weighted logistic regression with multiple imputation (m=5) was performed. Interaction models were used to identify effect modification. Results: The overall incidence of CA-AKI was similar in SGLT2i users (9.25%) and non-users (9.20%; adjusted OR 0.89, 95% CI 0.54–1.49, P=0.661). Hemoglobin (Hb) significantly modified the association (interaction OR 0.754 per 1 g/dL increase, P-interaction=0.023); the adjusted odds ratio crossed 1.0 at an estimated Hb level of 11.2 g/dL. SGLT2i use was associated with higher risk below this threshold and lower risk above it. Age also significantly modified the association (interaction OR 1.036 per year, P-interaction=0.037), with the interaction curve crossing the null at 72.4 years. A significant interaction by sex was observed (P-interaction=0.022), with a trend toward higher risk among females. Conclusion: While the overall association between SGLT2 inhibitor use and CA-AKI was neutral, baseline hemoglobin and age significantly modified this association. Periprocedural SGLT2i management may require individualized consideration, particularly in elderly patients with low hemoglobin levels.
원문(PDF)	PDF 원문보기

목록

위로가기